Haemonetics Analyst Ratings
Haemonetics Analyst Ratings
Haemonetics 分析師評級
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 26.69% | Barrington Research | $111 → $114 | Maintains | Outperform |
| 05/12/2023 | 23.36% | Barrington Research | $103 → $111 | Maintains | Outperform |
| 05/12/2023 | 6.69% | Morgan Stanley | $88 → $96 | Maintains | Equal-Weight |
| 05/12/2023 | 27.81% | JMP Securities | $105 → $115 | Maintains | Market Outperform |
| 02/08/2023 | -2.2% | Morgan Stanley | $84 → $88 | Maintains | Equal-Weight |
| 02/08/2023 | 5.58% | Citigroup | $92 → $95 | Maintains | Neutral |
| 02/08/2023 | 14.47% | Barrington Research | $94 → $103 | Maintains | Outperform |
| 02/08/2023 | 27.81% | Mizuho | $110 → $115 | Maintains | Buy |
| 01/24/2023 | 22.25% | Mizuho | $100 → $110 | Maintains | Buy |
| 01/06/2023 | -6.65% | Morgan Stanley | $90 → $84 | Maintains | Equal-Weight |
| 12/12/2022 | 2.24% | Citigroup | $88 → $92 | Maintains | Neutral |
| 11/08/2022 | 4.47% | Barrington Research | $88 → $94 | Maintains | Outperform |
| 11/08/2022 | 0.02% | Morgan Stanley | $85 → $90 | Maintains | Equal-Weight |
| 11/08/2022 | 11.14% | Mizuho | $90 → $100 | Maintains | Buy |
| 11/08/2022 | 16.69% | JMP Securities | $90 → $105 | Maintains | Market Outperform |
| 11/08/2022 | 11.14% | Raymond James | $88 → $100 | Maintains | Outperform |
| 11/08/2022 | -2.2% | Citigroup | $80 → $88 | Maintains | Neutral |
| 10/13/2022 | 0.02% | Mizuho | → $90 | Initiates Coverage On | → Buy |
| 10/11/2022 | -5.53% | Morgan Stanley | $74 → $85 | Maintains | Equal-Weight |
| 08/11/2022 | 0.02% | JMP Securities | $80 → $90 | Maintains | Market Outperform |
| 08/11/2022 | -17.76% | Morgan Stanley | $70 → $74 | Maintains | Equal-Weight |
| 08/11/2022 | -2.2% | Barrington Research | $77 → $88 | Maintains | Outperform |
| 08/11/2022 | -2.2% | Raymond James | $76 → $88 | Maintains | Outperform |
| 07/01/2022 | -22.2% | Morgan Stanley | $60 → $70 | Maintains | Equal-Weight |
| 07/01/2022 | -15.54% | Raymond James | $63 → $76 | Maintains | Outperform |
| 05/11/2022 | -33.32% | Morgan Stanley | $64 → $60 | Maintains | Equal-Weight |
| 05/11/2022 | -29.98% | Raymond James | $66 → $63 | Maintains | Outperform |
| 02/09/2022 | -26.65% | Raymond James | $70 → $66 | Maintains | Outperform |
| 01/27/2022 | — | Needham | Downgrades | Buy → Hold | |
| 01/07/2022 | -33.32% | Morgan Stanley | $68 → $60 | Maintains | Equal-Weight |
| 12/15/2021 | — | Citigroup | Downgrades | Buy → Neutral | |
| 11/10/2021 | -11.09% | JMP Securities | $90 → $80 | Maintains | Market Outperform |
| 11/10/2021 | -22.2% | Raymond James | $75 → $70 | Maintains | Outperform |
| 06/17/2021 | -16.65% | Citigroup | → $75 | Initiates Coverage On | → Buy |
| 05/14/2021 | — | CJS Securities | Upgrades | Market Perform → Outperform | |
| 05/14/2021 | 0.02% | JMP Securities | $110 → $90 | Maintains | Market Outperform |
| 05/14/2021 | -5.53% | Jefferies | $105 → $85 | Maintains | Buy |
| 05/14/2021 | -16.65% | Morgan Stanley | $83 → $75 | Maintains | Equal-Weight |
| 04/20/2021 | -7.76% | Morgan Stanley | $147 → $83 | Downgrades | Overweight → Equal-Weight |
| 04/20/2021 | 20.03% | Needham | $158 → $108 | Maintains | Buy |
| 04/20/2021 | 1.13% | Barrington Research | $140 → $91 | Maintains | Outperform |
| 04/19/2021 | 20.03% | Needham | $158 → $108 | Maintains | Buy |
| 02/12/2021 | 72.26% | Raymond James | $145 → $155 | Maintains | Outperform |
| 02/03/2021 | 55.59% | Barrington Research | → $140 | Upgrades | Market Perform → Outperform |
| 02/03/2021 | 63.37% | Morgan Stanley | $139 → $147 | Maintains | Overweight |
| 02/03/2021 | 61.15% | Raymond James | $135 → $145 | Maintains | Outperform |
| 01/21/2021 | — | Barrington Research | Downgrades | Outperform → Market Perform | |
| 01/20/2021 | 57.81% | Needham | $122 → $142 | Maintains | Buy |
| 01/07/2021 | 50.03% | Raymond James | $130 → $135 | Maintains | Outperform |
| 12/15/2020 | 54.48% | Morgan Stanley | $110 → $139 | Maintains | Overweight |
| 11/05/2020 | — | Barrington Research | Upgrades | Market Perform → Outperform | |
| 11/02/2020 | 44.48% | Raymond James | $100 → $130 | Maintains | Outperform |
| 09/08/2020 | 11.14% | Raymond James | $93 → $100 | Maintains | Outperform |
| 08/05/2020 | 3.36% | Raymond James | $113 → $93 | Maintains | Outperform |
| 07/08/2020 | 22.25% | Morgan Stanley | $138 → $110 | Maintains | Overweight |
| 07/01/2020 | 25.58% | Raymond James | $125 → $113 | Maintains | Outperform |
| 05/06/2020 | 38.92% | Raymond James | $130 → $125 | Maintains | Outperform |
| 05/05/2020 | 46.7% | Needham | $142 → $132 | Maintains | Buy |
| 04/07/2020 | 44.48% | Raymond James | $150 → $130 | Maintains | Outperform |
| 03/27/2020 | 53.37% | Morgan Stanley | $148 → $138 | Maintains | Overweight |
| 02/05/2020 | 66.7% | Raymond James | $145 → $150 | Maintains | Outperform |
| 01/23/2020 | 61.15% | Raymond James | $150 → $145 | Maintains | Outperform |
| 01/10/2020 | 53.37% | Needham | → $138 | Initiates Coverage On | → Buy |
| 08/07/2019 | 64.48% | Morgan Stanley | $128 → $148 | Maintains | Overweight |
| 08/07/2019 | 66.7% | Raymond James | $110 → $150 | Maintains | Outperform |
| 05/14/2019 | 22.25% | Raymond James | → $110 | Upgrades | Market Perform → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 26.69% | 巴靈頓研究公司 | $111→$114 | 維護 | 跑贏大盤 |
| 2023年05月12日 | 23.36% | 巴靈頓研究公司 | $103→$111 | 維護 | 跑贏大盤 |
| 2023年05月12日 | 6.69% | 摩根士丹利 | $88→$96 | 維護 | 等重 |
| 2023年05月12日 | 27.81% | JMP證券 | $105→$115 | 維護 | 市場表現強於大盤 |
| 02/08/2023 | -2.2% | 摩根士丹利 | $84→$88 | 維護 | 等重 |
| 02/08/2023 | 5.58% | 花旗集團 | $92→$95 | 維護 | 中性 |
| 02/08/2023 | 14.47% | 巴靈頓研究公司 | $94→$103 | 維護 | 跑贏大盤 |
| 02/08/2023 | 27.81% | 瑞穗 | $110→$115 | 維護 | 買 |
| 01/24/2023 | 22.25% | 瑞穗 | $100→$110 | 維護 | 買 |
| 01/06/2023 | -6.65% | 摩根士丹利 | $90→$84 | 維護 | 等重 |
| 2022年12月12日 | 2.24% | 花旗集團 | $88→$92 | 維護 | 中性 |
| 11/08/2022 | 4.47% | 巴靈頓研究公司 | $88→$94 | 維護 | 跑贏大盤 |
| 11/08/2022 | 0.02% | 摩根士丹利 | $85→$90 | 維護 | 等重 |
| 11/08/2022 | 11.14% | 瑞穗 | $90→$100 | 維護 | 買 |
| 11/08/2022 | 16.69% | JMP證券 | $90→$105 | 維護 | 市場表現強於大盤 |
| 11/08/2022 | 11.14% | 雷蒙德·詹姆斯 | $88→$100 | 維護 | 跑贏大盤 |
| 11/08/2022 | -2.2% | 花旗集團 | $80→$88 | 維護 | 中性 |
| 10/13/2022 | 0.02% | 瑞穗 | →$90 | 開始承保 | →購買 |
| 2022年10月11日 | -5.53% | 摩根士丹利 | $74→$85 | 維護 | 等重 |
| 2022年08月11日 | 0.02% | JMP證券 | $80→$90 | 維護 | 市場表現強於大盤 |
| 2022年08月11日 | -17.76% | 摩根士丹利 | $70→$74 | 維護 | 等重 |
| 2022年08月11日 | -2.2% | 巴靈頓研究公司 | $77→$88 | 維護 | 跑贏大盤 |
| 2022年08月11日 | -2.2% | 雷蒙德·詹姆斯 | $76→$88 | 維護 | 跑贏大盤 |
| 07/01/2022 | -22.2% | 摩根士丹利 | $60→$70 | 維護 | 等重 |
| 07/01/2022 | -15.54% | 雷蒙德·詹姆斯 | $63→$76 | 維護 | 跑贏大盤 |
| 2022年05月11日 | -33.32% | 摩根士丹利 | $64→$60 | 維護 | 等重 |
| 2022年05月11日 | -29.98% | 雷蒙德·詹姆斯 | $66→$63 | 維護 | 跑贏大盤 |
| 02/09/2022 | -26.65% | 雷蒙德·詹姆斯 | $70→$66 | 維護 | 跑贏大盤 |
| 2022年01月27日 | - | 李約瑟 | 評級下調 | 購買→Hold | |
| 01/07/2022 | -33.32% | 摩根士丹利 | $68→$60 | 維護 | 等重 |
| 2021年12月15日 | - | 花旗集團 | 評級下調 | 購買→中性 | |
| 2021年11月10日 | -11.09% | JMP證券 | $90→$80 | 維護 | 市場表現強於大盤 |
| 2021年11月10日 | -22.2% | 雷蒙德·詹姆斯 | $75→$70 | 維護 | 跑贏大盤 |
| 06/17/2021 | -16.65% | 花旗集團 | →$75 | 開始承保 | →購買 |
| 2021/05/14 | - | CJS證券 | 升級 | 市場表現優於→ | |
| 2021/05/14 | 0.02% | JMP證券 | $110→$90 | 維護 | 市場表現強於大盤 |
| 2021/05/14 | -5.53% | 傑富瑞 | $105→$85 | 維護 | 買 |
| 2021/05/14 | -16.65% | 摩根士丹利 | $83→$75 | 維護 | 等重 |
| 04/20/2021 | -7.76% | 摩根士丹利 | $147→$83 | 評級下調 | 超重→等重 |
| 04/20/2021 | 20.03% | 李約瑟 | $158→$108 | 維護 | 買 |
| 04/20/2021 | 1.13% | 巴靈頓研究公司 | $140→$91 | 維護 | 跑贏大盤 |
| 04/19/2021 | 20.03% | 李約瑟 | $158→$108 | 維護 | 買 |
| 02/12/2021 | 72.26% | 雷蒙德·詹姆斯 | $145→$155 | 維護 | 跑贏大盤 |
| 02/03/2021 | 55.59% | 巴靈頓研究公司 | →$140 | 升級 | 市場表現優於→ |
| 02/03/2021 | 63.37% | 摩根士丹利 | $139→$147 | 維護 | 超重 |
| 02/03/2021 | 61.15% | 雷蒙德·詹姆斯 | $135→$145 | 維護 | 跑贏大盤 |
| 2021/01/21 | - | 巴靈頓研究公司 | 評級下調 | 跑贏→市場表現 | |
| 01/20/2021 | 57.81% | 李約瑟 | $122→$142 | 維護 | 買 |
| 01/07/2021 | 50.03% | 雷蒙德·詹姆斯 | $130→$135 | 維護 | 跑贏大盤 |
| 12/15/2020 | 54.48% | 摩根士丹利 | $110→$139 | 維護 | 超重 |
| 11/05/2020 | - | 巴靈頓研究公司 | 升級 | 市場表現優於→ | |
| 11/02/2020 | 44.48% | 雷蒙德·詹姆斯 | $100→$130 | 維護 | 跑贏大盤 |
| 09/08/2020 | 11.14% | 雷蒙德·詹姆斯 | $93→$100 | 維護 | 跑贏大盤 |
| 08/05/2020 | 3.36% | 雷蒙德·詹姆斯 | $113→$93 | 維護 | 跑贏大盤 |
| 07/08/2020 | 22.25% | 摩根士丹利 | $138→$110 | 維護 | 超重 |
| 07/01/2020 | 25.58% | 雷蒙德·詹姆斯 | $125→$113 | 維護 | 跑贏大盤 |
| 05/06/2020 | 38.92% | 雷蒙德·詹姆斯 | $130→$125 | 維護 | 跑贏大盤 |
| 05/05/2020 | 46.7% | 李約瑟 | $142→$132 | 維護 | 買 |
| 04/07/2020 | 44.48% | 雷蒙德·詹姆斯 | $150→$130 | 維護 | 跑贏大盤 |
| 03/27/2020 | 53.37% | 摩根士丹利 | $148→$138 | 維護 | 超重 |
| 02/05/2020 | 66.7% | 雷蒙德·詹姆斯 | $145→$150 | 維護 | 跑贏大盤 |
| 1/23/2020 | 61.15% | 雷蒙德·詹姆斯 | $150→$145 | 維護 | 跑贏大盤 |
| 2020/10/01 | 53.37% | 李約瑟 | →$138 | 開始承保 | →購買 |
| 2019年08月07日 | 64.48% | 摩根士丹利 | $128→$148 | 維護 | 超重 |
| 2019年08月07日 | 66.7% | 雷蒙德·詹姆斯 | $110→$150 | 維護 | 跑贏大盤 |
| 2019年05月14日 | 22.25% | 雷蒙德·詹姆斯 | →$110 | 升級 | 市場表現優於→ |
What is the target price for Haemonetics (HAE)?
血液科技(HAE)的目標價格是多少？
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on August 9, 2023. The analyst firm set a price target for $114.00 expecting HAE to rise to within 12 months (a possible 26.69% upside). 23 analyst firms have reported ratings in the last year.
Barrington Research於2023年8月9日報道了Haemonetics(紐約證券交易所代碼：HAE)的最新目標價。這家分析公司將目標價定為114.00美元，預計恆生指數將在12個月內上漲至26.69%。過去一年，23家分析公司公佈了評級。
What is the most recent analyst rating for Haemonetics (HAE)?
血液科技(HAE)的最新分析師評級是多少？
The latest analyst rating for Haemonetics (NYSE: HAE) was provided by Barrington Research, and Haemonetics maintained their outperform rating.
血液公司(紐約證券交易所代碼：HAE)的最新分析師評級是由巴靈頓研究公司提供的，血液公司維持其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Haemonetics (HAE)?
血液學(HAE)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Haemonetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Haemonetics was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與血液科技的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。血液學的上一次評級是在2023年8月9日提交的，所以你應該預計下一次評級將在2024年8月9日左右提供。
Is the Analyst Rating Haemonetics (HAE) correct?
分析師對血液學(HAE)的評級正確嗎？
While ratings are subjective and will change, the latest Haemonetics (HAE) rating was a maintained with a price target of $111.00 to $114.00. The current price Haemonetics (HAE) is trading at is $89.98, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的血液科技(HAE)評級保持不變，目標價在111.00美元至114.00美元之間。血液科技(HAE)目前的交易價格為89.98美元，超出了分析師的預測範圍。